负载异体肿瘤细胞裂解物的自体树突状细胞在胰腺癌患者中诱导肿瘤反应性T细胞反应:一项I期研究
这项I期研究纳入10例根治性切除后无影像学复发征象的胰腺导管腺癌(PDAC)患者,给予负载异体肿瘤裂解物的自体单核细胞来源树突状细胞(DC)疫苗,在第0、2、4周及第3、6个月注射。DC制备与给药均成功,所有患者出现1级注射部位及输注相关反应,2例出现2级发热,1例出现3级呼吸困难,未见疫苗相关严重不良事件。疫苗与患者肿瘤间存在共享肿瘤抗原,所有可评估患者均出现疫苗诱导的免疫反应。
要点
- 10例切除后无复发征象的PDAC患者接受异体肿瘤裂解物负载的自体DC疫苗。
- 所有患者出现1级注射部位及输注相关反应,2例2级发热,1例3级呼吸困难,无疫苗相关严重不良事件。
- 所有可评估患者均出现疫苗诱导的循环T细胞反应,并检测到针对自体肿瘤的T细胞反应性。
核心结论
- 异体肿瘤裂解物-DC治疗可行、安全,并可诱导针对PDAC表达抗原的免疫反应性。
研究设计与样本
- I期研究,纳入标准治疗后在影像学上无复发征象的切除后PDAC患者,共10例。
- 疫苗为负载异体肿瘤裂解物的自体单核细胞来源DC,于第0、2、4周及第3、6个月注射。
- 研究目标为异体肿瘤-DC的可行性、安全性和免疫原性,并检测疫苗与患者肿瘤间共享的肿瘤抗原。
- 对外周血、皮肤和肿瘤进行免疫学分析。
主要发现
- DC制备和给药均成功。
- 所有患者出现1级注射部位及输注相关反应,2例出现2级发热,1例出现3级呼吸困难。
- 未观察到疫苗相关严重不良事件。
- 在疫苗与患者肿瘤之间发现共享肿瘤抗原。
- 所有可评估患者均显示疫苗诱导的反应,表现为Ki67+和活化PD-1+循环T细胞频率增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is notorious for its poor prognosis even after curative resection. Responses to immunotherapy are rare and related to inadequate T-cell priming. We previously demonstrated the potency of allogeneic lysate-dendritic cell (DC) vaccination in a preclinical model. Here we translate this concept to patients. METHODS: In this phase I study, patients with resected PDAC were included when they demonstrated no radiologic signs of recurrence after standard-of-care treatment. Allogeneic tumour lysate-loaded autologous monocyte-derived DCs were injected at weeks 0, 2, 4 and at months 3 and 6. Objectives are feasibility, safety and immunogenicity of allogeneic tumour-DCs. The presence of tumour antigens shared between the vaccine and patient tumours was investigated. Immunological analyses were performed on peripheral blood, skin and tumour. RESULTS: Ten patients were included. DC production and administration were successful. All patients experienced a grade 1 injection-site and infusion-related reaction. Two patients experienced a grade 2 fever and 1 patient experienced a grade 3 dyspnoea. No vaccine-related serious adverse events were observed. Shared tumour antigens were found between the vaccine and patient tumours. All evaluated patients displayed a vaccine-induced response indicated by increased frequencies of Ki67+ and activated PD-1+ circulating T-cells. In addition, treatment-induced T-cell reactivity to autologous tumour of study patients was detected. Seven out of ten patients have not experienced disease recurrence or progression at a median follow-up of 25 months (15-32 months). CONCLUSION: Allogeneic tumour lysate-DC treatment is feasible, safe and induces immune reactivity to PDAC expressed antigens.
引用
- Lau SP, Klaase L, Vink M, et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. Eur J Cancer. 2022. PMID: 35490565. doi:10.1016/j.ejca.2022.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。